Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

REFERENCES

• Wong WL, Su X, Li X et al. Global prevalence of age‐related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. Lancet Global Health 2014; 2: 106–116.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Pharmacokinetics, pharmacodynamics and pre‐clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014; 7: 167–180.
   PubMed Web of Science ®Google Scholar
• Zampros I, Praidou A, Brazitikos P et al. Anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration. J Ophthalmol 2012; 2012: 319728.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Duse S et al. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013; 7: 711–722.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Aflibercept (VEGF Trap‐Eye) for the treatment of exudative age‐related macular degeneration. Expert Rev Clin Pharmacol 2013; 6: 103–113.
   PubMed Web of Science ®Google Scholar
• Fassnacht‐riederle H, Becker M, Graf N et al. Effect of aflibercept in insufficient responders to prior anti‐VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1705–1709.
   Web of Science ®Google Scholar
• Cheung CM, Mohle A, Wong TY. Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept. Eye 2014; 28: 1148–1149.
   Web of Science ®Google Scholar
• Hata M, Oishi A, Tsujikawa A et al. Efficacy of intravitreal injection of aflibercept in neovascular age‐related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci 2014; 55: 7874–7880.
   PubMed Web of Science ®Google Scholar
• Miller JW, Schmidt‐erfurth U, Sickenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age‐related macular degeneration: results of a single treatment in a phase 1and 2 study. Arch Ophthalmol 1999; 177: 1161–1173.
   Google Scholar
• Klein R, Klein BE, Jensen SC et al. The five‐year incidence and progression of age‐related maculopathy: the Beaver Dam Eye Study. Ophthalmol 1997; 104: 7–21.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap‐eye) in wet age‐related macular degeneration. Ophthalmol 2012; 119: 2537–2548.
   PubMed Web of Science ®Google Scholar
• Hirakata T, Fujinami K, Watanabe K et al. One‐year outcome of intravitreal aflibercept injection for age‐related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement. Clin Ophthalmol 2016; 10: 969–977.
   Web of Science ®Google Scholar
• Maringe E, Letesson E, Duncombe A et al. Evaluation of the efficacy of aflibercept's in the treatment of neovascular age‐related macular degeneration in treatment‐naive and switched patients. Reports of 86 cases. J Fr Ophthalmol 2016; 39: 255–260.
   Web of Science ®Google Scholar
• Delaey C, Van de voorde J. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res 2000; 32: 249–256.
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995–1002.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Devy L et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186–3193.
   PubMed Web of Science ®Google Scholar
• Branchini L, Regatieri C, Adhi M et al. Effect of intravitreous anti‐vascular endothelial growth factor therapy on choroidal thickness in neovascular age‐related macular degeneration using spectral‐domain optical coherence tomography. JAMA Ophthalmol 2013; 131: 693–694.
   PubMed Web of Science ®Google Scholar
• Hikichi T, Kitamei H, Shioya S et al. Relation between changes in foveal choroidal thickness and 1‐year results of ranibizumab therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol 2014; 98: 1201–1204.
   Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age‐related macular degeneration: twelve‐month results. Ophthalmol 2016; 123: 617–624.
   PubMed Web of Science ®Google Scholar
• Kaya F. Change in choroidal thickness after intravitreal injection for treatment of neovascular age‐related macular degeneration: Ranibizumab versus aflibercept. J Fr Ophtalmol 2017; 40: 832–838.
   Web of Science ®Google Scholar
• Mazaraki K, Fassnacht‐riederle H, Blum R et al. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment‐naive eyes for neovascular age‐related macular degeneration. Br J Ophthalmol 2015; 99: 1341–1344.
   PubMed Web of Science ®Google Scholar
• Hera R, Keramidas M, Peoc'h M et al. Expression of VEGF and angiopoetins in subfoveal membranes from patients with age‐related macular degeneration. Am J Ophthalmol 2005; 139: 589–596.
   PubMed Web of Science ®Google Scholar